Oncology Compass’ Post

Primum is starting a new monthly article series to surface the best oncology publications. Primum will work with a select group of oncology fellows to find, rate, and summarize interesting, recently published articles. Oncology fellows rate each article on a scale of 1 to 10 describing the likelihood the work will be implemented in their practice. This first set of articles focuses on advances in lung and breast cancer treatment. The oncology fellows have discussed drugs like LIBTAYO® (cemiplimab-rwlc) HCP, OPDIVO® (nivolumab) US HCP, and Ibrance. To read more and understand a few oncology fellows’ opinions about these recent articles, fill in your information here: https://lnkd.in/ggBtQapZ #oncology #communityoncology

A discussion with Balazs Halmos for mNSCLC with actionable mutations in 1L : Oncology Brothers Rahul Gosain, MD, MBA Rohit Gosain, MD Roswell Park Comprehensive Cancer Center #Cancer #FightAgainstCancer #Oncodaily #Oncology #LungCancer 

Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology - Ankit Mangla JAMA Oncology John Kirkwood National Comprehensive Cancer Network® (NCCN®) #Cancer #CheckpointInhibitors #ClinicalTrials #JAMAOncology #Melanoma #OncoDaily #Oncology #PathologicalResponse #RadiologicalResponse

Discussions around practice-changing cancer therapies and care approaches were abundant at ASCO 2024. In this piece for Pharma Phorum, experts from IQVIA dissect some of the most noteworthy oncology advances shared during this year’s meeting – including increasing insights on blood cancers via late-stage outcomes, and AI/ML’s role in supporting faster and more accurate care. https://bit.ly/3Yymugx #ASCO24 #oncology

Equip your team with the insight they need to make decisions. Stay competitive with Oncology Resource Group's Pipeline Strategies Reports. Endometrial cancer is evolving fast with a flurry of new approvals, including two this month. ONCrg stays on top of the news, big and small, to save you time. Contact Brittany Daggett to see more of our ONCrg Pipeline Strategies: Endometrial Cancer report, or for other solid tumors, hematologic malignancies, and MOAs. Unrivaled Insights, Unmatched Expertise #oncology #competitivestrategy #endometrialcancer #competitivelandscape

A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - Neeraj Agarwal, MD, FASCO Rana McKay Alicia Morgans OncoAlert UroToday + GU OncToday Prostate Cancer Foundation #Cancer #OncoDaily #Oncology #ProstateCancer

 A comprehensive review of PARPi+ARPI combos in 1st line mCRPC

An analysis of patient-reported outcomes (PROs) from the phase 3 CAPItello-291 trial (NCT04305496) showed positive health-related quality-of-life (HRQOL) outcomes with capivasertib (Truqap) plus fulvestrant (Faslodex) among those with aromatase inhibitor (AI)-resistant hormone receptor-positive/HER2-negative advanced breast cancer. Findings were presented at the 2023 San Antonio Breast Cancer Symposium. #SABCS23 #Oncology #Nursing #BreastCancer #BCSM #OncologyNursing #CancerCare #NursePractitioner https://lnkd.in/gaZUwmFv

🌟 Exciting News! 🌟 I am thrilled to announce the publication of our latest article in the American Journal of Clinical Oncology: **"Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in the Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis."** In this comprehensive study, we delve into the therapeutic potential of PARP inhibitors for patients with BRCA-mutated breast cancer, evaluating both their efficacy and safety. Our findings provide valuable insights that can help guide clinical decisions and improve patient outcomes. 🔍 **Key Highlights:** - Systematic review and meta-analysis of the latest clinical trials - Detailed evaluation of the therapeutic benefits and adverse effects of PARP inhibitors - Implications for personalized treatment strategies in BRCA-mutated breast cancer I want to extend my heartfelt thanks to my co-authors and collaborators for their dedication and hard work. Your expertise and commitment made this research possible. Read the full article here: [Efficacy and Safety of BRCA-targeted Therapy](https://lnkd.in/gbWf2j5M) #breastcancer #BRCA #PARPinhibitors #oncology #clinicalresearch #systematicreview #metaanalysis

Ovarian Cancer Research Alliance hosted a discussion during our spring Industry Council meeting that offered insight around the opportunities of broadening the focus among stakeholders from a single gynecologic cancer to all gynecologic cancers, with perspectives shared by clinicians, patient advocates, industry partner GSK, and others. Read a meeting recap and learn more about our Industry Council at bit.ly/4bDqtMA. #GynecologicOncology #Oncology #CancerResearch